Passive antibody therapies: Progress and continuing challenges

Clinical Immunology

Volumn 93, Issue 1, 1999, Pages 5-15

  Casadevall, Arturo ^a,b  

^a Division of Infectious Diseases   (United States)

^b Dept Microbiol Immunol Albert E ^*  (United States)

Author keywords

Immunotherapy; Monoclonal antibody; Serum therapy

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG COST; DRUG INDICATION; DRUG RESEARCH; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; IMMUNOTOXICITY; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

EID: 0032819934     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4768     Document Type: Review

References (84)

1. Casadevall A., Scharff M. D. "Serum therapy" revisited: Animal models of infection and the development of passive antibody therapy. Antimicrob. Agents Chemother. 38:1994;1695-1702.
2. Casadevall A., Scharff M. D. Return to the past: The case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21:1995;150-161.
3. Glatman-Freedman A., Casadevall A. Serum therapy for tuberculosis revisited: A reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin. Microbiol. Rev. 11:1998;514-532.
4. Watt C. H. Poisonous snakebite treatment in the United States. J. Am. Med. Assoc. 240:1978;654-656.
5. Smith T. W., Butler V. P., Haber E., Fozzard H., Marcus F. I., Bremmer W. F., Schulman I. C., Phillips A. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. N. Engl. J. Med. 307:1982;1357-1362.
6. Good R. A., Lorenz E. Historic aspects of intravenous immunoglobulin therapy. Cancer. 68:1991;1415-1421.
7. Dickler H. B., Gelfand E. W. Current perspectives on the use of intravenous immunoglobulin. Adv. Int. Med. 41:1997;641-680.
8. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
9. Wright A., Shin S.-U., Morrison S. L. Genetically engineered antibodies: Progress and prospects. Crit. Rev. Immunol. 12:1992;125-168.
10. Kang A. S., Burton D. R., Lerner R. A. Combinatorial immunoglobulin libraries in phage. Methods: Companion Methods Enzymol. 2:1991;111-118.
11. Rader C., Barbas C. F. III. Phage display of combinatorial antibody libraries. Curr. Opin. Biotechnol. 8:1997;503-508.
12. Hayden M. S., Gilliland L. K., Ledbetter J. A. Antibody engineering. Curr. Opin. Immunol. 9:1997;201-212.
13. Mendez M. J., Green L. L., Corvalan J. R. F., Jia X., Maynard-Currie C. E., Yang X., Gallo M. L., Louie D. M., Lee D. V., Erickson K. L., Luna J., Roy C. M. N., Abderrahim H., Kirschenbaum F., Noguchi M., Smith D. H., Fukushima A., Hales J. F., Finer M. H., Davis C. G., Zsebo K. M., Jakobovits A. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genet. 15:1997;146-156.
14. Ma J.-K. C., Hein M. B. Immunotherapeutic potential of antibodies produced in plants. Trends Biotechnol. 13:1997;522-527.
15. Nadler L. M., Stashenko P., Hardy R., Kaplan W. D., Button L. N., Kufe D. W., Antman K., Schlossman S. F. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40:1980;3147-3154.
16. Miller R. A., Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet. 2:1981;226-230.
17. Meeker T., Lowder J., Cleary M. L., Stewart S., Warnke R., Sklar J., Levy R. Emergence of idiotype negative variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312:1985;1658-1665.
18. Raffeld M., Neckers L., Longo D. L., Cossman J. Spontaneous alteration of idiotype in a monoclonal B cell lymphoma. Escape from detection by anti-idiotype. N. Engl. J. Med. 312:1985;1653-1658.
19. Wilde M. I., Goa K. L. Muromonab CD3. A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 51:1999;865-894.
20. Warren H. S., Danner R. L., Munford R. S. Anti-endotoxin monoclonal antibodies. N. Engl. J. Med. 326:1994;1153-1156.
21. M. M. W. R. 34:1985;895-900.
22. Hibbs R. C., Weber J. T., Corwin A., Allos R. M., El Rechim M. S. A., El Sharkawy S., Sarn J. E., McKee K. T. Jr. Experience with the use of an investigational F(ab′)2 heptavalent bolulism immune globulin of equine origin during an outbreak of Type E botulism in Egypt. Clin. Infect. Dis. 23:1996;337-340.
23. Gold B. S., Wingert W. A. Snake venom poisoning in the United States. South. Med. J. 67:1994;579-589.
24. Rappolt R. T., Quinn H., Curtis L., Minton S. A., Murphy J. B. Medical toxicologist's notebook: Snakebite treatment and international antivenin index. Clin. Toxicol. 13:1978;409-438.
25. Warny M., Fatimi A., Bostwick E. F., Laine D. C., Lebel F., LaMont J. T., Pothoulakis C., Kelly C. P. Bovine immunoglobulin concentrate - Clostridium difficile retains C. difficile toxin neutralizing activity after passage through the human stomach and small intestine. Gut. 44:1999;212-217.
26. Keutsch G. T. The rediscovery of shiga toxin and its role in human illness. Infect. Dis. Clin. Prac. 6:1997;533-536.
27. Lewis J. M., Baranberg L. H. The use of convalescent serum in the treatment of measles, chicken-pox, mumps and whooping cough, including the prophylactic value of parental blood. N. Y. State J. Med. 33:1933;97-99.
28. Moudgil A., Shidban H., Nast C. C., Bagga A., Aswad S., Graham S. L., Mendez R., Jordan S. C. Parvovirus B19 infection-related complications in renal transplant recipients. Transplantation. 64:1997;1847-1850.
29. Casadevall A., Goldman D. L., Feldmesser M. Antibody-based therapies for infectious diseases: Renaissance for an abandoned arsenal. Bull. Inst. Pasteur. 95:1997;247-257.
30. Jahrling P. B., Geisbert J., Swearengen J. R., Jaax G. P., Lewis T., Huggins J. W., Schmidt J. J., LeDuc J. W., Peters C. J. Passive immunizatio of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. 11:1996;135-140.
31. Storch G. A. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics. 102:1998;648-651.
32. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., Neylan J., Wilkinson A., Ekberg H., Gaston R., Lackman L., Burdick J. Interleukin-2-receptor blockade with dacliuzmab to prevent acute rejection in renal transplantation. N. Engl. J. Med. 338:1998;161-165.
33. Baert F. J., D'Haens G. R., Peeters M., Hiele M. I., Schaible T. F., Shealy D., Geboes K., Rutgeerts P. J. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 116:1999;22-28.
34. Targan S. R., Hanauer S. B., van Devender S. J. H., Mayer L., Present D. H., Braakman T., DeWoody M. S., Schaible T. F., Rutgeerts P. J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N. Engl. J. Med. 337:1999;1029-1035.
35. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliot M. J., Woody J. N., Schaible T. B., Feldman M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1999;1552-1563.
36. Corne J., Djukanovic R., Thomas L., Warner J., Bottan L., Grandordy B., Gygax D., Heusser C., Patalano F., Richardson W., Kilchherr E., Staehelin T., Davis F., Gordon W., Sun L., Liou R., Wang G., Chang T., Holgate S. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics. J. Clin. Invest. 99:1997;879-887.
37. Demoly P., Bousquet J. Anti-IgE therapy for asthma. Am. J. Respir. Crit. Care Med. 155:1997;1825-1827.
38. Topol E. J., Byzova T. V., Plow E. F. Platelet GPIIb-IIIa blockers. Lancet. 353:1999;227-231.
39. Riethmuller G., Schneider-Gadicke E., Johnson J. P. Monoclonal antibodies in cancer therapy. Curr. Opin. Immunol. 5:1993;732-739.
40. Pollyblank A. M., Monson J. R. T. Monoclonal antibody treatment of colorectal cancer. Br. J. Surg. 84:1997;1511-1517.
41. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg. Infect. Dis. 2:1996;200-208.
42. Lang A. B., Cryz S. J., Schurch U., Ganss M. T., Bruderer U. Immunotherapy with human monoclonal antibodies. J. Immunol. 151:1993;466-472.
43. Wilde H., Thipkong P., Sitprija V., Chaiyabutr N. Heterologous antisera and antivenin are essential biologicals: Perspectives on a worldwide crisis. Ann. Intern. Med. 125:1996;233-236.
44. Slade H. B. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin. Diagn. Lab. Immunol. 1:1994;613-619.
45. Kuss-Reichel K., Grauer L., Karavodin L. M., Knott C., Krusemeier M., Kay N. E. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies. Clin. Diagn. Lab. Immunol. 1:1994;365-372.
46. Lang J., Attanath P., Quiambao B., Singhasivanon V., Chanthavanich P., Montalban C., Lutsch C., Pepin-Covatta S., Le Mener V., Miranda M., Sabchareon A. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered alone or in combination with a purified, Vero-cell rabies vaccine. Acta Trop. 70:1998;317-333.
47. Stein K. E. Overcoming obstacles to monoclonal antibody product development and approval. Trends Biotechnol. 15:1997;88-90.
48. Zuckier L. S., Rodrigues L. D., Scharff M. D. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin. Nucl. Med. 19:1989;166-186.
49. Schroff R. W., Foon K. A., Beatty S. M., Oldham R. K., Morgan A. C. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45:1985;879-885.
50. Hank J. A., Albertini M., Wesly O. H., Schiller J. H., Borchert A., Moore K., Bechhofer R., Storer B., Gan J., Gambacorti C., Sosman J., Sondel P. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer. Clin. Cancer Res. 1:1995;481-491.
51. Pulito V. L., Roberts V. A., Adair J. R., Rothermel A. L., Collins A. M., Varga S. S., Martocello C., Bodmer M., Jolliffe L. K., Zivin R. A. Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKY4A. J. Immunol. 156:1996;2840-2850.
52. Smith J. A., Bluestone J. A. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr. Opin. Immunol. 9:1997;648-654.
53. Waiser J., Budde K., Schreiber M., Böhler T., Löbermann L.-A., Neumayer H.-H. Antibody therapy in steroid-resistant rejection. Transplant. Proc. 30:1999;1778-1779.
54. Vossen A. C. T. M., Tibbe G. J. M., Kroos M. J., van de Winkel J. G. J., Benner R., Savelkoul H. F. J. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur. J. Immunol. 25:1995;1492-1496.
55. Yuki N., Yamada M., Tagawa Y., Takahashi H., Handa S. Pathogenesis of the neurotoxicity caused by anti-CD2 antibody therapy. J. Neurol. Sci. 149:1997;127-130.
56. Munda R., Hutchins M., First M. R., Carey M., Schroeder T., Alexander J. W. Infection in OKT3-treated patients receiving additional antirejection therapy. Transplant. Proc. 21:1989;1763-1765.
57. MMWR. 43:1994;1-38.
58. Blake P. A., Feldman R. A., Buchanan T. M., Brooks G. F., Bennett J. V. Serologic therapy of tetanus in the United States. J. Am. Med. Assoc. 42:1976;235-244.
59. Kelly C. P., Keates S., Bostwick E. F., Roush A. M., Castagliuolo I., LaMont J. T., Pothoulakis C. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob. Agents Chemother. 41:1997;236-241.
60. Tacket C. O., Shandera W. X., Mann J. M., Hargrett N. T., Blake P. A. Equine antitoxin use and other factors that predict outcome in Type A foodborne botulism. Am. J. Med. 76:1984;794-798.
61. Barry W., Hudgins H., Donta S. T., Pesanti E. L. Intravenous immunoglobulin therapy for toxic shock syndrome. J. Am. Med. Assoc. 267:1992;3315-3316.
62. Aulitzky W. E., Schulz T. F., Niederwieser D., Larcher K., Ostberg L., Scriba M., Martindale J., Stern A. C., Grass P., Mach M., Dierich M. P., Huber C. Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: Report of a phase I trial in bone marrow transplant patients. J. Infect. Dis. 163:1991;1344-1347.
63. Cavacini L. A., Samore M. H., Gambertoglio J., Jackson B., Duval M., Wisnewski A., Hammer S., Koziel C., Trapnell C., Posner M. R. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV-1 glycoprotein 120. AIDS Res. Hum. Retroviruses. 14:1998;545-550.
64. Zolla-Pazner S., Gorny M. K. Passive immunization for the prevention and treatment of HIV infection. AIDS. 6:1992;1235-1247.
65. Clayton A. J. Lassa immune serum. Bull WHO. 55:1977;435-439.
66. Björn N., Moore R., Amlot P., Schmidt A., Abeywickrama K., Soulillou J. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 350:1997;1193-1198.
67. Borowitz S. M., Saulsbury F. T. Treatment of chronic cryptosporidial infection with orally administered human serum immune globulin. J. Pediatr. 119:1991;593-595.
68. Shield J., Melville C., Novelli V., Anderson G., Scheimberg I., Gibb D., Milla P. Bovine colostrum immunoglobulin concentrate for cryptosporidiosis in AIDS. Arch. Dis. Child. 69:1993;451-453.
69. Whittle M. J. Rhesus haemolytic disease. Arch. Dis. Child. 67:1995;65-68.
70. Leget G. A., Czuczman M. S. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10:1998;548-551.
71. Chippaux J. P., Goyffon M. Producers of antivenomous sera. Toxicon. 21:1983;739-752.
72. Goldenberg M. M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21:1999;309-318.
73. Kelley M. J., Linnoila R. I., Avis I. L., Georgiades M. S., Cuttitta R., Mulshine J. L., Johnson B. E. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 112:1997;256-261.
74. Brooks D., Taylor C., Dos Santos B., Linden H., Houghton A., Hecht T. T., Kornfeld S., Taetle R. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin. Cancer Res. 1:1995;1259-1265.
75. Goodrick J., Kumpel B., Pamphilon D., Fraser I., Chapman G., Dawes B., Anstee D. Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers. Clin. Exp. Immunol. 98:1994;17-20.
76. Prsepiorka D., Phillips G. L., Ratanatharathorn V., Cottler-Fox M., Sehn L. H., Antin J. H., LeBherz D., Awwad M., Hope J., McClain J. B. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood. 92:1996;4066-4071.
77. Pawson R., Dyer M. J., Barger R., Matutes E., Thornton P. D., Emmett E., Kluin-Nelemans J. C., Fibber W. E., Willemze R., Catovsky D. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol. 15:1997;2667-2672.
78. Hale G., Zhang M., Bunjes D., Prentice H. G., Spence D., Horowitz M. M., Barret A. J., Waldman H. Improving the outcome of bone marrow transplantation using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 92:1999;4581-4590.
79. Racine-Poon A., Botta L., Chang T. W., Davis F. M., Gygax D., Liou R. S., Rohane P., Staehelin T., van Steijn A. M. P., Frank W. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, and anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin. Pharmacol. Ther. 62:1997;675-690.
80. Salmela K., Wramner L., Ekberg H., Hauser I., Bentdal Ø., Lins L., Isoniemi H., Backman L., Persson N., Neumayer H., Jorgensen P., Spiefer C., Hendry B., Nicholls A., Kirste G., Hasche G. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation. Transplantation. 67:1999;729-738.
81. Bowen J. D., Petersdorf S. H., Richards T. L., Maravilla K. R., Dale D. R., Price T. H., St. John T. P., Yu S. A. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin. Pharmacol. Ther. 64:1998;339-346.
82. Yocum D. E., Solinger A. M., Tesser J., Gluck O., Cornett M., O'Sullivan F., Nordensson K., Dallaire B., Shen C. D., Lipani J. Clinical and immunologic effects of PRIMATIZED anti-CD4 monoclonal antibody in active rheumatodi arthritis: Results of a phase I, single dose, dose escalating trial. J. Rheumatol. 25:1998;1257-1262.
83. Kon O. M., Sihra B. S., Compton C. H., Leonard T. B., Kay A. B., Barnes N. C. Randominzed, dose-ranging, placebo-controlled study of chimeric anctioby to CD4 (keliximab) in chronic severe asthma. Lancet. 352:1998;1109-1113.
84. Moreland L. W., Haverty T. P., Wacholtz M. C., Knowles R. W., Bucy R. P., Heck L. W. Jr., Koopman W. J. Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis. J. Rheumatol. 25:1998;221-228.